PwPepwise

Thymalin

Anti-Aging & Longevity

Thymic peptide complex

Thymalin is a natural polypeptide extract derived from the thymus gland, a central organ of the immune system.

§Dosing at a glance

3 protocols · from the research
What it's forDoseHow oftenHowFor how long
Severe COVID-19 (immunomodulation)10 mgOnce dailyIntramuscularInjected into a muscle.10 days
General immunomodulation / COVID-19 adjunct therapy10 mgDaily——
Animal research reference dose10 mgDailySubcutaneousInjected just under the skin, into the fat layer.12 mos

Approximate values pulled from the research — double-check before dosing.

§01Summary

Thymalin is a natural polypeptide extract derived from the thymus gland, a central organ of the immune system. It contains a mixture of bioactive peptides — including the dipeptide L-Glu-L-Trp — that appear to support immune function by promoting the maturation and activity of T-lymphocytes, the white blood cells responsible for coordinating immune responses4. As the thymus shrinks with age (a process called thymic involution), thymalin has been investigated as a way to restore immune competence in older adults and in patients with conditions that suppress immune function.

Early human studies suggest thymalin may improve key immune markers — including T-cell counts and the balance between immune-activating and immune-suppressing cells — in conditions ranging from chronic hepatitis B12 to pulmonary tuberculosis10 and acute peritonitis13. In elderly patients, it has been reported to be associated with reductions in mortality and infectious disease incidence over multi-year follow-up1,9, though the magnitude of these reported effects is unusually large and the studies have important methodological limitations. More recently, thymalin has been explored as an adjunct therapy in severe COVID-19, where it has been reported to accelerate recovery of lymphocyte counts and reduce inflammatory markers such as IL-6, C-reactive protein, and D-dimer6,16. Animal research suggests it may also slow age-related cancer development3. Thymalin's evidence base is actively developing, with human studies spanning several decades and multiple disease areas.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Thymalin is a heterogeneous polypeptide preparation extracted from bovine thymus tissue, consisting of a complex mixture of low-molecular-weight bioactive peptides. Its principal characterized active constituent is the dipeptide L-glutamyl-L-tryptophan (L-Glu-L-Trp), isolated from the native extract by HPLC3. The preparation acts primarily as a thymic hormone mimetic, targeting the T-lymphocyte compartment to restore immune competence in states of immunodeficiency or immunosenescence.

At the cellular level, thymalin and its constituent peptides stimulate T-lymphocyte differentiation from precursor cells, enhance T-cell recognition of peptide-MHC complexes, and modulate intracellular second messengers including cyclic nucleotides4. These events drive downstream secretion of cytokines including interleukin-2 (IL-2) and interferon (IFN), which amplify adaptive immune responses4. The synthetic dipeptide derivatives additionally activate neutrophil chemotaxis and phagocytosis, suggesting effects extending into innate immunity4. A mechanistically important distinction between natural thymalin extract and synthetic dipeptide analogs is that thymalin demonstrates antioxidant activity in thymocytes that synthetic compounds lack, implying that the complex peptide mixture confers biological properties beyond those of any single isolated component4.

Thymalin also appears to function as a cytokine antagonist in the context of inflammatory regulation, modulating the balance between pro- and anti-inflammatory signaling4. In the context of severe COVID-19, its administration has been reported to shift macrophage phenotype from pro-inflammatory M1 (CD86+) toward reparative M2 (CD163+) polarization7, suppress neutrophil/lymphocyte and platelet/lymphocyte ratios8,15,18, and reduce circulating levels of fibrinogen, D-dimer, and lactate dehydrogenase — markers associated with immunothrombosis8,15. These observations are consistent with a mechanism involving attenuation of cytokine storm dynamics and resolution of coagulation dysregulation.

In aging models, L-Glu-L-Trp administration reduced the Gompertz aging rate constant (from 0.0071 to 0.0041 days⁻¹), suggesting a biological deceleration of aging kinetics rather than a simple shift in survival3. A proposed mechanistic basis involves short peptide binding to double-stranded DNA and histone proteins to regulate the activity of gerontogenes — genes implicated in age-related biological decline16, though this mechanism is being characterized through ongoing molecular research. Anti-tumor effects observed in rodent models are consistent with enhanced immunosurveillance via T-cell and neutrophil activation, with the dissociation between antibody levels and protective efficacy in parasitic infection models further implicating cell-mediated rather than humoral immunity as the primary effector mechanism20. Formal pharmacokinetic parameters including half-life, bioavailability, and metabolic pathways in humans are an area of active investigation.

§04Evidence & efficacy

Evidence base
219Studies
104Human
56Animal

Thymalin has been reported to improve cellular immune markers across multiple human studies. In severe COVID-19, it may accelerate recovery of CD4+ T-cell counts2, normalize lymphocyte and monocyte counts8,15,18, and accelerate reductions in pro-inflammatory markers including IL-6, C-reactive protein, and D-dimer6,16. In elderly COVID-19 patients, thymalin has been reported to be associated with approximately 50% lower hospital mortality compared to standard therapy alone in non-randomized comparisons15,16, and one study with randomization reported a significant reduction in in-hospital mortality (19.4% vs. 40.9%, p=0.04)2, though baseline immune parameter imbalances between groups complicate interpretation of this result.

In long-term observational studies of elderly patients, thymalin has been reported to be associated with 2.0–2.1-fold reductions in mortality over 6–8 years, with combination therapy reportedly achieving up to 4.1-fold reductions in a subgroup receiving annual treatment1,9. Acute respiratory disease incidence and clinical manifestations of ischemic heart disease, hypertension, osteoarthrosis, and osteoporosis were also reported to be reduced1,9.

In earlier human studies, thymalin may improve immune cell profiles and produce clinico-biochemical remission in chronic viral hepatitis B12, accelerate resolution of acute peritonitis13, and improve outcomes in advanced cervical carcinoma when combined with radiotherapy11. In pulmonary tuberculosis, thymalin was one of several immunocorrectors associated with clinical benefit when introduced early in therapy10.

In animal models, the dipeptide constituent L-Glu-L-Trp — isolated from thymalin — significantly extended maximum lifespan and reduced spontaneous tumor incidence, including a 3.4-fold reduction in hematopoietic malignancies, in rats3. A single thymalin dose reduced peritoneal cysticerci burden by 54.9% in a murine parasitic infection model20, and sub-therapeutic dose administration achieved tumor regression in more than 50% of rats with transplanted sarcoma5.

§05Safety

Across the available studies, thymalin appears to be well-tolerated, with no adverse events explicitly reported in any human or animal study included in this analysis1,2,3,5,6,8,9,10,12,13,20. This includes use in vulnerable populations such as critically ill COVID-19 patients — including elderly individuals and those requiring mechanical ventilation2,6,8 — as well as patients with chronic hepatitis B12, acute peritonitis13, and advanced cervical carcinoma11. In the animal literature, no tolerability signals were identified over 12 months of subcutaneous administration in rats3 or following single-dose administration in mice20.

No drug interactions have been formally reported. One study noted that the combination of thymalin with heparin was particularly beneficial for elderly patients at thromboembolic risk, suggesting the combination was clinically manageable13. The immunostimulatory effect of combined thymogen (a related synthetic thymic dipeptide) plus interferon therapy in tuberculosis patients was associated with more pronounced residual lung changes following healing of fibrous deformity, a finding that may be relevant to combination immunostimulatory regimens more broadly10, though thymalin as a monotherapy did not demonstrate this pattern.

Long-term safety data and formal pharmacovigilance assessments are areas of active research, consistent with thymalin's status as an investigational agent outside of Russia and Eastern Europe.

§06History

Thymalin was developed in the Soviet Union during the 1970s and 1980s by Vladimir Khavinson and Vladimir Morozov at what is now the St. Petersburg Institute of Bioregulation and Gerontology. It emerged from a research program aimed at isolating biologically active peptides from endocrine and immune tissues for therapeutic use, paralleling contemporaneous Western interest in thymic hormones such as thymosin and thymulin. Early clinical applications focused on immune dysfunction, with studies in the 1980s reporting benefits in acute peritonitis13 and chronic viral hepatitis B12, establishing thymalin's immunomodulatory profile in Soviet clinical practice.

During the 1990s, research expanded to examine thymalin alongside synthetic dipeptide derivatives (Thymogen, Vilon) for chronic pathology and immune dysfunction4, and its application in oncology began to emerge, including use in cervical carcinoma11 and pulmonary tuberculosis10. A landmark gerontological program initiated in the 1980s and reported in the early 2000s claimed multi-fold reductions in mortality in elderly patients treated annually over 6–8 years1,9, generating significant interest in thymalin as a geroprotective agent.

In parallel, animal research demonstrated that L-Glu-L-Trp — identified as a principal active dipeptide within thymalin — significantly extended maximum lifespan and suppressed spontaneous carcinogenesis in rodents3. Following the COVID-19 pandemic, thymalin was investigated as an immunomodulatory adjunct in severe COVID-19, with multiple Russian clinical studies published between 2021 and 20232,6,8,15,16,18,19. Thymalin remains approved and in clinical use in Russia, while its regulatory status in Western countries is that of an investigational compound.

§07References